PL1670514T3 - Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II - Google Patents

Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II

Info

Publication number
PL1670514T3
PL1670514T3 PL04773539T PL04773539T PL1670514T3 PL 1670514 T3 PL1670514 T3 PL 1670514T3 PL 04773539 T PL04773539 T PL 04773539T PL 04773539 T PL04773539 T PL 04773539T PL 1670514 T3 PL1670514 T3 PL 1670514T3
Authority
PL
Poland
Prior art keywords
inhibitor
topoisomerase
histone deacetylase
antitumor agent
deacetylase inhibitor
Prior art date
Application number
PL04773539T
Other languages
English (en)
Inventor
Yoshinori Naoe
Yuka Sasakawa
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of PL1670514T3 publication Critical patent/PL1670514T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
PL04773539T 2003-09-25 2004-09-24 Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II PL1670514T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2003334340 2003-09-25
JP2003344315 2003-10-02
EP04773539A EP1670514B1 (en) 2003-09-25 2004-09-24 Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
PCT/JP2004/014451 WO2005030239A2 (en) 2003-09-25 2004-09-24 Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor

Publications (1)

Publication Number Publication Date
PL1670514T3 true PL1670514T3 (pl) 2010-11-30

Family

ID=34380371

Family Applications (2)

Application Number Title Priority Date Filing Date
PL04773539T PL1670514T3 (pl) 2003-09-25 2004-09-24 Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II
PL10163527T PL2263694T3 (pl) 2003-09-25 2004-09-24 Środek przeciwnowotworowy zawierający FK228 jako inhibitor deacetylazy histonowej i doksorubicynę jako inhibitor topoizomerazy II

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL10163527T PL2263694T3 (pl) 2003-09-25 2004-09-24 Środek przeciwnowotworowy zawierający FK228 jako inhibitor deacetylazy histonowej i doksorubicynę jako inhibitor topoizomerazy II

Country Status (14)

Country Link
US (1) US7314862B2 (pl)
EP (2) EP2263694B1 (pl)
JP (1) JP4779971B2 (pl)
AT (1) ATE471740T1 (pl)
CA (1) CA2540108A1 (pl)
CY (1) CY1114359T1 (pl)
DE (1) DE602004027824D1 (pl)
DK (1) DK2263694T3 (pl)
ES (2) ES2425083T3 (pl)
MX (1) MXPA06003222A (pl)
PL (2) PL1670514T3 (pl)
PT (1) PT2263694E (pl)
SI (1) SI2263694T1 (pl)
WO (1) WO2005030239A2 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2298414C2 (ru) * 2001-08-21 2007-05-10 Астеллас Фарма Инк. Медицинское применение ингибитора гистоновой дезацетилазы и способ оценки его противоопухолевого действия
EP1492596A1 (en) * 2002-04-05 2005-01-05 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2004074478A1 (ja) * 2003-02-19 2004-09-02 Astellas Pharma Inc. ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法
US7375228B2 (en) * 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
DE602004027824D1 (de) 2003-09-25 2010-08-05 Astellas Pharma Inc Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US7642275B2 (en) * 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008540574A (ja) * 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CA2615105A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007040522A1 (en) * 2005-09-30 2007-04-12 The Ohio State Research Foundation Antitumor agents
CA2630216A1 (en) * 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the hdac inhibitor fk228
EP1976835A2 (en) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US9539303B2 (en) * 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
PT2099442E (pt) * 2006-12-26 2015-02-10 Pharmacyclics Inc Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
EP2102230A2 (en) 2006-12-29 2009-09-23 Gloucester Pharmaceuticals, Inc. Purifiction of romidepsin
CN103497238A (zh) * 2006-12-29 2014-01-08 细胞基因公司 制备Romidepsin
US8034768B2 (en) * 2007-06-22 2011-10-11 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by histone deacetylase inhibitors
US20110021517A1 (en) * 2008-02-26 2011-01-27 Nerviano Medical Sciences S.R.L. Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
CN103108648A (zh) 2010-07-12 2013-05-15 细胞基因公司 罗米地辛固体形式及其用途
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
UA110853C2 (uk) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
JP6253591B2 (ja) * 2012-11-01 2017-12-27 公益財団法人微生物化学研究会 抗がん剤、及び併用抗がん剤
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN116327887B (zh) * 2023-04-24 2023-11-03 南京捷因诊断技术有限公司 一种lsd1抑制剂作为抗肿瘤药物的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US574455A (en) * 1897-01-05 Switch-lock
US486379A (en) * 1892-11-15 Hame-tug
US3997633A (en) * 1975-06-24 1976-12-14 Max Leva Contact towers with leak-proof support of improved plate subassembly
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4348388A (en) * 1980-04-02 1982-09-07 G.D. Searle & Co. 11-Amino-11-deoxydaunorubicin and analogs
GB8426672D0 (en) * 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
US4950755A (en) * 1985-08-12 1990-08-21 Ohio State University Bis(morpholinomethyl) derivative of 1,2-bis(dioxopiperizinyl)propane
US5242901A (en) * 1988-01-27 1993-09-07 New York University Reduction of anthracycline induced cardiotoxicity
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
JPH05507480A (ja) * 1990-05-26 1993-10-28 ビイク　グルデン　ロンベルク　ヒエーミツシエ　フアブリーク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング 医薬品抵抗性の克服の際に使用するための１，４―ジヒドロピリジン
US5620961A (en) * 1994-04-25 1997-04-15 Markovic; Nenad S. Fructose ester-β-cyclodextrin complexes and processes for making and using same
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US6020373A (en) * 1995-10-20 2000-02-01 Eastern Virginia Medical School Chelate derivatives as protectors against tissue injury
US5780054A (en) * 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
NZ336381A (en) * 1996-12-30 2000-11-24 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6451784B1 (en) * 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6286513B1 (en) * 1998-10-22 2001-09-11 Jessie L. Au Methods for treating superficial bladder carcinoma
US6197809B1 (en) * 1998-12-23 2001-03-06 Ardenia Investments Ltd. Compounds for the treatment of cancer
US20030144570A1 (en) * 1999-11-12 2003-07-31 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
KR20100035666A (ko) * 1999-11-23 2010-04-05 메틸진 인크. 히스톤 디아세틸라제의 억제제
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
EP1246839B1 (en) 1999-12-08 2004-06-16 Xcyte Therapies, Inc. Depsipeptide and congeners thereof for use as immunosuppressants
US20020028237A1 (en) * 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
ATE425177T1 (de) 2000-07-17 2009-03-15 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
WO2002024178A2 (en) * 2000-09-22 2002-03-28 Bristol-Myers Squibb Company Method for reducing toxicity of combined chemotherapies
JP2004525860A (ja) * 2000-09-22 2004-08-26 ブリストル−マイヤーズ スクイブ カンパニー 併用化学療法剤の毒性を低下させる方法
US20020156023A1 (en) * 2000-12-06 2002-10-24 Tularik Inc. Lometrexol combination therapy
US20030099960A1 (en) * 2001-01-26 2003-05-29 The University Of Chicago Compositions and methods for optimizing UGT2B7 substrate dosings and for predicting UGT2B7 substrate toxicity
ATE450265T1 (de) * 2001-03-23 2009-12-15 Shire Canada Inc Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
RU2298414C2 (ru) * 2001-08-21 2007-05-10 Астеллас Фарма Инк. Медицинское применение ингибитора гистоновой дезацетилазы и способ оценки его противоопухолевого действия
EP1492596A1 (en) 2002-04-05 2005-01-05 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
NZ535992A (en) * 2002-05-17 2008-11-28 Aventis Pharma Sa Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
AU2003301251A1 (en) * 2002-10-15 2004-05-04 Ferx Incorporated Magnetically guided particles for radiative therapies
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
WO2004064727A2 (en) 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
WO2004103358A2 (en) 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
EP1638541B1 (en) 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
DE602004027824D1 (de) 2003-09-25 2010-08-05 Astellas Pharma Inc Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent

Also Published As

Publication number Publication date
DK2263694T3 (da) 2013-08-26
ES2425083T3 (es) 2013-10-11
MXPA06003222A (es) 2006-05-22
WO2005030239A2 (en) 2005-04-07
CA2540108A1 (en) 2005-04-07
EP2263694B1 (en) 2013-06-12
ATE471740T1 (de) 2010-07-15
JP2007506647A (ja) 2007-03-22
DE602004027824D1 (de) 2010-08-05
EP2263694A1 (en) 2010-12-22
US20050070467A1 (en) 2005-03-31
PT2263694E (pt) 2013-08-27
WO2005030239A3 (en) 2005-07-28
JP4779971B2 (ja) 2011-09-28
EP1670514B1 (en) 2010-06-23
US7314862B2 (en) 2008-01-01
CY1114359T1 (el) 2016-08-31
ES2344899T3 (es) 2010-09-09
PL2263694T3 (pl) 2013-11-29
EP1670514A2 (en) 2006-06-21
SI2263694T1 (sl) 2013-09-30

Similar Documents

Publication Publication Date Title
SI2263694T1 (sl) Antitumorsko sredstvo, ki obsega inhibitor histon-deacetilaze FK228 in inhibitor topoizomeraze II doksorubicin
TW200738725A (en) Unsaturated mTOR inhibitors
TW200801006A (en) Fused bicyclic mTOR inhibitors
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
TW200626131A (en) C-aryl glucoside SGLT2 inhibitors and method
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
WO2009156735A3 (en) New therapeutic agents
TW200519111A (en) N3-substituted imidazopyridine C-KIT inhibitors
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
WO2003080582A3 (de) Fredericamycin-derivate
IL164599A0 (en) Combination therapy for the treatment of cancer
AU2002246728A1 (en) Carboline derivatives
AU2002364211A1 (en) Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2002340168A1 (en) Treatment of prostate cancer by inhibitors of ncam2
AU2002249890A1 (en) Carboline derivatives
MXPA03010761A (es) Combinaciones farmaceuticas.
DE60322417D1 (en) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1,8-naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
AU2002347747A1 (en) Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
TW200508199A (en) Novel compound